(Q36939259)

17 August 2017

1 reference

title

Metabolic syndrome: from global epidemiology to individualized medicine (English)

1 reference

17 August 2017

1 reference

1 reference

J A Batsis

1

1 reference

17 August 2017

R E Nieto-Martinez

series ordinal

2

1 reference

17 August 2017

F Lopez-Jimenez

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

12 September 2007

1 reference

Clinical Pharmacology & Therapeutics

17 August 2017

1 reference

17 August 2017

82

1 reference

17 August 2017

509-524

1 reference

17 August 2017

5

1 reference

Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology

17 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

Prediction of Coronary Heart Disease Using Risk Factor Categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

AHA Science Advisory: Lyon Diet Heart Study. Benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

The relationship between serum triglycerides and skinfold thickness in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The metabolic syndrome--a new worldwide definition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Comment on the provisional report from the WHO consultation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Lowering the criterion for impaired fasting glucose is in order

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Criteria for central obesity in a Brazilian population: impact on metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Prevalence of metabolic syndrome in a semi-arid rural area in Bahia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Prevalence of the metabolic syndrome and associated lifestyles in adult males from Oaxaca, Mexico.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Quality of life among postmenopausal Ecuadorian women participating in a metabolic syndrome screening program

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Type 2 diabetes and metabolic syndrome in Filipina-American women : a high-risk nonobese population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Overweight and obesity in the United States: prevalence and trends, 1960-1994

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Prevalence of overweight and obesity in the United States, 1999-2004

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The metabolic syndrome: prevalence in worldwide populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Metabolic syndrome in urban Asian Indian adults--a population study using modified ATP III criteria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Effect of lifestyle intervention on metabolic coronary heart disease risk factors in obese older adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Metabolic syndrome and risk of cardiovascular disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Age, gender and metabolic syndrome-related coronary heart disease in U.S. adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The prevalence of the metabolic syndrome did not increase in Mexico City between 1990-1992 and 1997-1999 despite more central obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The Usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III Definitions of the Metabolic Syndrome in Predicting Coronary Heart Disease in Subjects With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Diabetes incidence in 0- to 14-year age-group in Italy: a 10-year prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Younger age at onset and sex predict celiac disease in children and adolescents with type 1 diabetes: an Italian multicenter study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Tumor necrosis factor-alpha is associated with increased protein C activation in nonobese type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Concordance between the 2005 International Diabetes Federation definition for diagnosing metabolic syndrome with the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization definitions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Population comparison of two clinical approaches to the metabolic syndrome: implications of the new International Diabetes Federation consensus definition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The threshold approach to clinical decision making.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Self-reported weight and height.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Insulin: in search of a syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The metabolic syndrome: requiescat in pace

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The metabolic syndrome, hyperlipidemia, and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Physical activity in the prevention of cardiovascular disease: an epidemiological perspective

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Physical activity energy expenditure predicts progression toward the metabolic syndrome independently of aerobic fitness in middle-aged healthy Caucasians: the Medical Research Council Ely Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Effects of exercise on metabolic risk variables in overweight postmenopausal women: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Independent and additive effects of energy restriction and exercise on glucose and insulin concentrations in sedentary overweight men.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Effects of aerobic or resistance exercise and/or diet on glucose tolerance and plasma insulin levels in obese men.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Metabolic syndrome, obesity, and mortality: impact of cardiorespiratory fitness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Soy inclusion in the diet improves features of the metabolic syndrome: a randomized crossover study in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Randomized trial of lifestyle modification and pharmacotherapy for obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

National trends in utilization and in-hospital outcomes of bariatric surgery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Safety and efficacy of bariatric surgery in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Bariatric surgery: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Effect of weight loss on predicted cardiovascular risk: change in cardiac risk after bariatric surgery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Effect of gastric bypass operation on Framingham and actual risk of cardiovascular events in class II to III obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Reduction in predicted coronary heart disease risk after substantial weight reduction after bariatric surgery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Impact of bariatric surgery on cardiovascular and musculoskeletal morbidity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Weight loss after Swedish Adjustable Gastric Banding: relationships to insulin resistance and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Changes in insulin sensitivity in morbidly obese patients with or without metabolic syndrome after gastric bypass

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Metabolic syndrome: yet another co-morbidity gastric bypass helps cure.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Effects of laparoscopic gastric banding on body composition, metabolic profile and nutritional status of obese women: 12-months follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Course of metabolic syndrome following the biliopancreatic diversion of Larrad

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Effects of obesity surgery on the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100355

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100355

1 reference

17 August 2017

1 reference